Morningstar

Samsung BioLogics Co Ltd 207940

Stock XKRX Rating as of Oct 1, 2026

News

Samsung Biologics publishes prospectus for PolyPeptide public tender offer

PR Newswire Aug 31, 2026, 5:00:00 AM
Samsung Biologics Seeks to Raise Over $2 Billion to Fund PolyPeptide Deal, Expansion — Update

Global News Select Aug 28, 2026, 2:21:00 AM
Samsung Biologics to Buy PolyPeptide Group for About $2 Billion

Global News Select Aug 28, 2026, 12:17:00 AM
Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion

PR Newswire Aug 27, 2026, 10:58:00 PM
Samsung Biologics Reports Second Quarter 2026 Financial Results

PR Newswire Jul 22, 2026, 11:03:00 PM
Samsung Biologics Offers to Buy PolyPeptide for Around $1.8 Billion

Global News Select Jul 20, 2026, 1:41:00 AM
Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India

PR Newswire Jul 19, 2026, 10:43:00 PM
Samsung Biologics Boosts U.S. Presence With $280 Million GSK Facility Deal

Global News Select Dec 22, 2025, 11:55:00 AM
South Korean Conglomerates Unveil Hiring Plans — Update

Global News Select Sep 18, 2025, 10:39:00 AM
Samsung Group to Add 60,000 Staff to Work on AI, Chips, Biotech

Global News Select Sep 18, 2025, 4:11:00 AM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.